Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission

Next Previous
Trial Profile

A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eflornithine (Primary)
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 15 Apr 2024 According to a Norgine media release, on 13 Dec 2023, the US Food and Drug Administration (FDA) approved eflornithine as the first oral maintenance therapy for high-risk neuroblastoma. The approval decision was based on findings from a trial comparing outcomes from Study 3b (NCT02395666; investigational arm) and Study ANBL0032 (NCT00026312; clinical-trial-derived external control arm).
    • 05 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2023 Results of Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons (from studies NCT02395666, NCT00026312)published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top